{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T20:28:11Z","timestamp":1790368091759,"version":"4.1.0"},"reference-count":23,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T00:00:00Z","timestamp":1766361600000},"content-version":"unspecified","delay-in-days":21,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Avalyn Pharma, Inc."}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Resp Res"],"accepted":{"date-parts":[[2025,10,12]]},"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Progressive pulmonary fibrosis (PPF) is a debilitating progression of pulmonary fibrosis in patients with interstitial lung diseases (ILDs) other than idiopathic pulmonary fibrosis (IPF). Oral pirfenidone has been studied in non-IPF ILDs, but in smaller academic studies, it did not achieve a statistically significant change in the primary endpoint. Increased systemic exposure with oral administration may lead to substantial adverse events and limit its utility. Clinical data support inhaled pirfenidone for the treatment of PPF with improved tolerability compared with orally administered pirfenidone.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>Approximately 300 patients with PPF will be randomised 2:1:2 to one of three treatment arms: AP01 100\u2009mg two times per day, AP01 50\u2009mg two times per day or placebo two times per day by oral inhalation using the investigational eFlow Nebuliser System (PARI Pharma GmbH, Germany). The primary endpoint is the change from baseline in forced vital capacity at week 52. The main secondary endpoints are change in quality of life measurements from baseline to 52 weeks, time to disease progression and change in lung fibrosis scores based on high-resolution CT from baseline to 52 weeks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT06329401\">NCT06329401<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjresp-2024-003059","type":"journal-article","created":{"date-parts":[[2025,12,25]],"date-time":"2025-12-25T09:30:15Z","timestamp":1766655015000},"page":"e003059","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Design of the MIST study: a double-blind, randomised, placebo-controlled phase 2b trial of pirfenidone solution for inhalation in patients with progressive pulmonary fibrosis"],"prefix":"10.1136","volume":"12","clinical-trial-number":[{"clinical-trial-number":"nct06329401","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct06329401","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Martin","family":"Kolb","sequence":"first","affiliation":[{"name":"McMaster University and Firestone Institute for Respiratory Health, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamera J","family":"Corte","sequence":"additional","affiliation":[{"name":"Royal Prince Alfred Hospital and University of Sydney, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Feldman","sequence":"additional","affiliation":[{"name":"Summit Health Eastside Clinic, Bend, Oregon, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven D","family":"Nathan","sequence":"additional","affiliation":[{"name":"Lung Transplant Program, Inova Fairfax Hospital, Falls Church, Virginia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin","family":"Reisner","sequence":"additional","affiliation":[{"name":"DevPro Biopharma, Basking Ridge, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepthi","family":"Nair","sequence":"additional","affiliation":[{"name":"Avalyn Pharma, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Woodhead","sequence":"additional","affiliation":[{"name":"Avalyn Pharma, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard","family":"Lazarus","sequence":"additional","affiliation":[{"name":"Avalyn Pharma, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"Conoscenti","sequence":"additional","affiliation":[{"name":"Avalyn Pharma, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,12,25]]},"reference":[{"key":"2026010701520211000_12.1.e003059.1","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.03187-2021","article-title":"Progressive pulmonary fibrosis: an expert group consensus statement","volume":"61","author":"Rajan","year":"2023","journal-title":"Eur Respir J"},{"key":"2026010701520211000_12.1.e003059.2","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1164\/rccm.202202-0399ST","article-title":"Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS\/ERS\/JRS\/ALAT Clinical Practice Guideline","volume":"205","author":"Raghu","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"2026010701520211000_12.1.e003059.3","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1097\/MCP.0000000000000908","article-title":"Epidemiology and real-life experience in progressive pulmonary fibrosis","volume":"28","author":"Valenzuela","year":"2022","journal-title":"Curr Opin Pulm Med"},{"key":"2026010701520211000_12.1.e003059.4","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02571-2021","article-title":"Prevalence and characteristics of progressive fibrosing interstitial lung disease in a prospective registry","volume":"60","author":"Hambly","year":"2022","journal-title":"Eur Respir J"},{"key":"2026010701520211000_12.1.e003059.5","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S2213-2600(19)30341-8","article-title":"Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"8","author":"Maher","year":"2020","journal-title":"Lancet Respir Med"},{"key":"2026010701520211000_12.1.e003059.6","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S2213-2600(20)30554-3","article-title":"Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial","volume":"9","author":"Behr","year":"2021","journal-title":"Lancet Respir Med"},{"key":"2026010701520211000_12.1.e003059.7","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1513\/AnnalsATS.202103-342OC","article-title":"Pirfenidone in Progressive Pulmonary Fibrosis: A Systematic Review and Meta-Analysis","volume":"19","author":"Ghazipura","year":"2022","journal-title":"Ann Am Thorac Soc"},{"key":"2026010701520211000_12.1.e003059.8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1908681"},{"key":"2026010701520211000_12.1.e003059.9","doi-asserted-by":"crossref","first-page":"123","DOI":"10.4046\/trd.2023.0119","article-title":"Progressive Pulmonary Fibrosis: Where Are We Now?","volume":"87","author":"Kang","year":"2024","journal-title":"Tuberc Respir Dis (Seoul)"},{"key":"2026010701520211000_12.1.e003059.10","doi-asserted-by":"crossref","first-page":"143","DOI":"10.3390\/cells11010143","article-title":"Differential Discontinuation Profiles between Pirfenidone and Nintedanib in Patients with Idiopathic Pulmonary Fibrosis","volume":"11","author":"Takehara","year":"2022","journal-title":"Cells"},{"key":"2026010701520211000_12.1.e003059.11","doi-asserted-by":"publisher","DOI":"10.1136\/thorax-2022-219391"},{"key":"2026010701520211000_12.1.e003059.12","doi-asserted-by":"crossref","unstructured":"West A , Lawrence A , Bao H , et al . Nebulised pirfenidone in idiopathic pulmonary fibrosis (ipf): first look at fvc data. Eur Respir J 2023;62. doi:10.1183\/13993003.congress-2023.OA2582","DOI":"10.1183\/13993003.congress-2023.OA2582"},{"key":"2026010701520211000_12.1.e003059.13","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00080312"},{"key":"2026010701520211000_12.1.e003059.14","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201604-0801CI"},{"key":"2026010701520211000_12.1.e003059.15","doi-asserted-by":"publisher","DOI":"10.1378\/chest.14-0492"},{"key":"2026010701520211000_12.1.e003059.16","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/S2213-2600(15)00093-4","article-title":"Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials","volume":"3","author":"Durheim","year":"2015","journal-title":"Lancet Respir Med"},{"key":"2026010701520211000_12.1.e003059.17","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1164\/rccm.202309-1708OC","article-title":"Hospitalization Rates in Interstitial Lung Disease: An Analysis of the Pulmonary Fibrosis Foundation Registry","volume":"210","author":"King","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"key":"2026010701520211000_12.1.e003059.18","doi-asserted-by":"crossref","first-page":"00016","DOI":"10.1183\/13993003.00016-2016","article-title":"2017 ERS\/ATS standards for single-breath carbon monoxide uptake in the lung","volume":"49","author":"Graham","year":"2017","journal-title":"Eur Respir J"},{"key":"2026010701520211000_12.1.e003059.19","doi-asserted-by":"publisher","DOI":"10.1378\/chest.14-2506"},{"key":"2026010701520211000_12.1.e003059.20","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2300083","article-title":"Nalbuphine Tablets for Cough in Patients with Idiopathic Pulmonary Fibrosis","volume":"2","author":"Maher","year":"2023","journal-title":"NEJM Evid"},{"key":"2026010701520211000_12.1.e003059.21","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00145-2020","article-title":"The Living with Pulmonary Fibrosis questionnaire in progressive fibrosing interstitial lung disease","volume":"7","author":"Swigris","year":"2021","journal-title":"ERJ Open Res"},{"key":"2026010701520211000_12.1.e003059.22","doi-asserted-by":"publisher","DOI":"10.1136\/thorax.58.4.339"},{"key":"2026010701520211000_12.1.e003059.23","doi-asserted-by":"crossref","first-page":"754851","DOI":"10.3389\/fphar.2021.754851","article-title":"Predictors of Mortality in Progressive Fibrosing Interstitial Lung Diseases","volume":"12","author":"Chen","year":"2021","journal-title":"Front Pharmacol"}],"container-title":["BMJ Open Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjresp-2024-003059","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T09:53:42Z","timestamp":1767779622000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopenrespres.bmj.com\/lookup\/doi\/10.1136\/bmjresp-2024-003059"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12,25]]},"published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10.1136\/bmjresp-2024-003059"],"URL":"https:\/\/doi.org\/10.1136\/bmjresp-2024-003059","relation":{},"ISSN":["2052-4439"],"issn-type":[{"value":"2052-4439","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12]]}}}